Biomarkers

Biomarkers for Alzheimer’s disease in a preclinical setting

The MIRIADE training program: development of dementia biomarkers

Upcoming plasma biomarkers for Alzheimer’s disease: Aβ, p-tau and GFAP

The accuracy of plasma biomarkers for Alzheimer’s disease outside of a controlled setting

Plasma biomarkers for Alzheimer’s disease as pre-screening tools

The promise of data science for the study of dementia

The potential of vaccination for neurodegenerative disease

The importance of pathologically defined cohorts in Alzheimer’s disease trials

Plasma NfL as a biomarker for frontotemporal dementia

Diagnostic tools for neurodegenerative disease

Improving clinical trials for Alzheimer’s disease therapies

The role of metabolism in the development of Alzheimer’s disease

Comparing the performance of novel biomarkers across the spectrum of Alzheimer’s disease

Using plasma biomarkers in the diagnosis of Alzheimer’s disease

Which plasma biomarkers hold the most promise in Alzheimer’s Disease?

Blood-based biomarkers for Alzheimer’s disease screening